Blackbryont Pharmaceuticals Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 29-07-2024
- Paid Up Capital ₹ 2.60 M
as on 29-07-2024
- Company Age 14 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.21 M
as on 29-07-2024
- Revenue 40.29%
(FY 2023)
- Profit -72.95%
(FY 2023)
- Ebitda -30.18%
(FY 2023)
- Net Worth 12.03%
(FY 2023)
- Total Assets 12.58%
(FY 2023)
About Blackbryont Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.60 M.
The company currently has active open charges totaling ₹4.21 M.
Jayagopal Narayanan, Shibu Kurian, Sugunan Mathilakath, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24232KL2009PTC024806
- Company No.
024806
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Sep 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Blackbryont Pharmaceuticals Private Limited offer?
Blackbryont Pharmaceuticals Private Limited offers a wide range of products and services, including Business Consultant, Facility Management Services.
Who are the key members and board of directors at Blackbryont Pharmaceuticals?
Executive Team (1)
JN
Jayagopal Narayanan
Managing DirectorAppointment Date: 01-Apr-2013
Status: Current
Board Members(6)
Financial Performance and Corporate Structure Insights of Blackbryont Pharmaceuticals.
Blackbryont Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 40.29% increase. The company also saw a substantial fall in profitability, with a 72.95% decrease in profit. The company's net worth Soared by an impressive increase of 12.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Blackbryont Pharmaceuticals?
In 2023, Blackbryont Pharmaceuticals had a promoter holding of 92.31% and a public holding of 7.69%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 03 Mar 2021 | ₹0.71 M | Open |
Uco Bank Creation Date: 20 Oct 2020 | ₹3.50 M | Open |
How Many Employees Work at Blackbryont Pharmaceuticals?
Unlock and access historical data on people associated with Blackbryont Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Sep 16, 2010, Blackbryont Pharmaceuticals has raised a total of ₹ 1.8 M, with the most recent deal valued at ₹ 1.8 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
